Jenkit eivät vielä pääse Eurooppaan, joten siltä osin vain odotetaan.
3.8. pitäisi tulla EMA:lta vastaus Euroopassa hyväksynnästä ja syyskuun tienoilla odotettavissa Kiinan päätös lääkkeen hyväksynnästä.
Tällainen löytyi sattumalta, julkaistu eilen:
WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA® (lefamulin) on a named patient or expanded access basis. The Named Patient Program (NPP) is designed to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving approval, can request IV or oral XENLETA on behalf of patients who live in certain countries where it is not yet available.
Siinä mainittiin EMA:n hyväksynnän tulevan H2 / 2020.
Ja tällainen mielenkiintoinen löytyi:
Pfizer, Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Bayer Pharmaceuticals, Merck KGaA and the American Merck — one of the last giants standing — are teaming up to create a $1 billion for-profit venture to bet on small biotechs developing mid-stage antibiotics, Ed Silverman reported for STAT.
Government officials from Germany, Sweden, France and the UK, as well as representatives from Wellcome Trust and Pew Charitable Trusts, will join the companies to announce the initiative on July 9, Silverman wrote. The World Health Organization and the European Investment Bank are also involved in what is being billed as a new solution to the “antibiotic innovation challenge.”
Tää menisi juuri Nabrivan tontille.